中国临床药理学杂志2025，Vol.41Issue(15)：2228-2235,8.DOI:10.13699/j.cnki.1001-6821.2025.15.022
胰高血糖素样肽-1受体激动药干预精神分裂症合并肥胖的临床研究现状
Research status of GLP-1 receptor agonists intervention in schizophrenia combined with obesity
摘要
Abstract
Patients with schizophrenia,who often require long-term antipsychotic medication,have an obesity incidence 3～5 times higher than that of the general population.As novel glucose-lowering and weight-reducing agents,GLP-1 receptor agonists(GLP-1RA)have demonstrated remarkable efficacy in the general population,yet their specific application in schizophrenia patients still awaits systematic evaluation.This article integrates existing research evidence to explore the current status of obesity in schizophrenia and the potential of GLP-1RA interventions.关键词
胰高血糖素样肽-1受体激动药/肥胖/精神分裂症/代谢综合征/抗精神病药物Key words
schizophrenia/obesity/glucagon-like peptide-1 receptor agonists/metabolic syndrome/antipsychotic drugs分类
医药卫生引用本文复制引用
单卓言,季善玲,林鑫玉,陈飞鸿,韩旭,郁昊,刘霞..胰高血糖素样肽-1受体激动药干预精神分裂症合并肥胖的临床研究现状[J].中国临床药理学杂志,2025,41(15):2228-2235,8.基金项目
国家自然科学基金资助项目(81901358) （81901358）
山东省自然科学基金资助项目(ZR2021YQ55) （ZR2021YQ55）
